Nicholas J. Short, MD

Articles

Understanding How to Best Measure MRD Negativity in Ph+ ALL

September 7th 2023

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

Tumor Lysis Syndrome: Unmet Needs and Future Directions in Care

February 7th 2023

Closing out their discussion on tumor lysis syndrome management, James Short, MD, and John Reagan, MD, highlight unmet needs and future evolutions in the treatment landscape.

TLS Management in Academic vs Community Centers of Care

February 7th 2023

A brief review of the differences that might be observed between tumor lysis syndrome management in an academic versus community setting.

Tumor Lysis Syndrome: Clinical Implications of Prophylaxis and Treatment

January 31st 2023

Experts James Short, MD, and John Reagan, MD, share comprehensive insight on the clinical implications of treating TLS in patients receiving therapy for cancer.

Guideline-Directed Treatment Options for Tumor Lysis Syndrome

January 31st 2023

James Short, MD, and John Reagan, MD, highlight guideline-indicated treatment options for patients with or at risk of tumor lysis syndrome.

Prophylactic Measures to Prevent Tumor Lysis Syndrome

January 24th 2023

Expert perspectives on prophylactic measures to prevent tumor lysis syndrome in patients receiving therapy for cancer.

Role of a Multidisciplinary Healthcare Team to Manage Tumor Lysis Syndrome

January 24th 2023

Shared insight on the multidisciplinary management of tumor lysis syndrome and how treatment planning may be adjusted after it is identified.

Identification of Tumor Lysis Syndrome: Signs and Symptoms

January 18th 2023

Comprehensive insight on the signs and symptoms that help lead to the identification of tumor lysis syndrome in patients receiving therapy for cancer.

Overview on Tumor Lysis Syndrome: Incidence and Risk Factors

January 18th 2023

Key opinion leaders James Short, MD, and John Reagan, MD, share an overview on the incidence and clinical risk factors of tumor lysis syndrome.

Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

August 4th 2022

Dr. Nicholas Short reviews updates to data on combination ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that were recently presented at the 2022 European Hematology Association (EHA) Congress.

Dr. Short on Ponatinib and Blinatumomab in Philadelphia Chromosome–Positive ALL

June 13th 2022

Nicholas J. Short, MD, discusses updated results from a single-arm phase 2 study investigating ponatinib plus blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL

June 7th 2021

Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia.